This campaign has been commissioned by an international Japanese pharmaceutical company who combat diseases using a combination of ground‐breaking technology and biology, with an extensive track record of academic collaboration. They are interested in AAV-based in vivo gene therapy through research programs for rare to common disease, and innovative gene regulation technologies.
Nov
28
Comments are closed.